International Immunopharmacology,
Journal Year:
2024,
Volume and Issue:
130, P. 111700 - 111700
Published: Feb. 20, 2024
Poststroke
inflammation
is
essential
in
the
mechanism
of
secondary
injury,
and
it
orchestrated
by
resident
microglia,
astrocytes,
circulating
immune
cells.
Edaravone
dexborneol
(EDB)
a
combination
edaravone
borneol
that
has
been
identified
as
clinical
protectant
for
stroke
management.
In
this
study,
we
verified
anti-inflammatory
effect
EDB
mouse
model
ischemia
investigated
its
modulatory
action
on
inflammation-related
C57BL/6
male
mice,
which
had
transient
middle
cerebral
artery
occlusion
(tMCAO),
were
treated
(i.p.)
with
(15
mg/kg).
administration
significantly
reduced
brain
infarction
improved
sensorimotor
function
after
stroke.
And
alleviated
neuroinflammation
restraining
polarization
microglia/macrophages
astrocyte
toward
proinflammatory
phenotype
inhibiting
production
cytokines
(such
IL-1β,
TNF-α,
IL-6)
chemokines
(including
MCP-1
CXCL1).
Furthermore,
ameliorated
MCAO-induced
impairment
Blood-brain
barrier
(BBB)
suppressing
degradation
tight
junction
protein
attenuated
accumulation
peripheral
leukocytes
ischemic
brain.
Additionally,
systemic
inhibited
macrophage
phenotypic
shift
M1
macrophage-dependent
inflammatory
response
spleen
blood.
Collectively,
protects
against
injury
activation
astrocytes
through
reduction
invasion
cells,
reduces
central
following
BMC Neurology,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: June 20, 2024
Abstract
Background
Edaravone
dexborneol
has
been
reported
as
an
effective
neuroprotective
agent
in
the
treatment
of
acute
ischemic
stroke
(AIS).
This
study
aimed
at
investigating
impact
edaravone
on
functional
outcomes
and
systematic
inflammatory
response
AIS
patient.
Methods
All
participants
were
recruited
from
AISRNA
(registered
21/11/2019,
NCT04175691
[ClinicalTrials.gov])
between
January
2022
December
2022.
The
patients
divided
into
two
groups
based
whether
they
received
(37.5
mg/12
hours,
IV)
within
48
h
after
onset.
Inflammatory
was
determined
by
detecting
levels
cytokines
(interleukin-2
[IL-2],
IL-4,
IL-5,
IL-8,
IL-6,
IL-10,
IL-12p70,
IL-17,
tumor
necrosis
factor-α
[TNF-α],
interferon-γ
[IFN-γ],
IFN-α,
IL-1β)
14
days
Results
Eighty-five
included
study.
Patients
treated
with
showed
a
significantly
higher
proportion
modified
Rankin
Scale
score
<
2
compared
to
those
who
did
not
receive
this
(70.7%
versus
47.8%;
P
=
0.031).
Furthermore,
individuals
receiving
injection
exhibited
lower
expression
interleukin
(IL)-1β,
along
IL-4
IL-10
during
phase
(
0.05).
These
trends
observed
for
IL-2,
factor-α,
IFN-α
>
Conclusions
Treatment
resulted
favorable
outcome
90
post-stroke
onset
when
without
intervention;
it
also
suppressed
proinflammatory
factors
while
increasing
anti-inflammatory
levels.
Trial
registration
ClinicalTrials.gov
NCT04175691.
Registered
November
21,
2019,
https://www.clinicaltrials.gov/ct2/show/NCT04175691
.
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 5, 2025
Chronic
cerebral
hypoperfusion
(CCH)
is
a
critical
pathophysiological
mechanism
underlying
small
vessel
disease
(CSVD).
Accumulating
evidence
have
demonstrated
that
resident
pericytes
and
deposit
extracellular
matrix
(ECM)
play
key
role
in
mediating
fibrosis
hypoxic
changes.
Edaravone
dexborneol
(EDB)
known
to
target
multiple
pathways
involved
fibrosis.
We
constructed
the
CCH
mouse
models
were
subjected
either
PBS
or
EDB
at
different
concentrations.
Measures
of
cognitive
function,
neuronal
damage,
white
matter
lesion
(WML),
fibrous
profiles
ECM
protein
investigated
assess
effect
EDB.
RNA
sequencing
OGD
was
performed
identify
signaling
pathway.
observed
both
medium
high
concentrations
could
ameliorate
CCH-induced
impairment
emotional
disorders.
Neuronal
damage
cortical
layer
hippocampus
WML
corpus
callosum
improved
by
EDB,
which
consistent
with
tends
proteins
these
regions.
suggested
TGF-β1/IL-11
plays
an
important
Subsequently,
results
confirmed
cellular
model.
Our
findings
reveal
pericyte-mediated
depositing
pathogenesis
CSVD.
improve
symptoms
mice
decrease
expression
proteins,
may
be
regulated
TGF-β1/
IL-11.
treatment,
targeting
fibrosis,
novel
therapeutic
strategy
for
Aging and Disease,
Journal Year:
2025,
Volume and Issue:
unknown, P. 0 - 0
Published: Jan. 1, 2025
Cerebral
small
vessel
disease
(CSVD)
is
a
common
in
older
people,
characterized
by
damage
to
intracranial
microvessels,
leading
cognitive
decline,
increased
risk
of
stroke,
and
dementia.
This
review
reviews
the
current
therapeutic
approaches
for
CSVD
latest
research
advances,
encompassing
traditional
pharmacological
therapies,
emerging
targeted
interventions
grounded
pathophysiology,
exploratory
immune-related
treatments,
advances
genetic
research.
In
addition,
role
lifestyle
modifications
management
discussed.
The
emphasizes
importance
holistic,
personalized
treatment
strategy
improve
outcomes.
More
clinical
trials
are
needed
validate
these
treatments
optimize
individualized
options
patients.
Stem Cell Research & Therapy,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 28, 2025
Acute
kidney
injury
(AKI)
is
a
major
global
public
health
concern
with
limited
treatment
options.
While
preclinical
studies
have
suggested
the
potential
of
mesenchymal
stem
cells
(MSCs)
to
repair
and
protect
injured
kidneys
in
AKI,
clinical
trials
using
transarterial
MSCs
transplantation
yielded
disappointing
results.
This
study
aimed
investigate
feasibility
safety
minimally
invasive
renal
subcapsular
for
treating
AKI
minipig
model,
ultimately
aiming
facilitate
translation
this
approach.
A
novel
model
was
established
by
combining
cisplatin
hydration
evaluate
effectiveness
therapies.
Renal
catheterization
successfully
achieved
under
ultrasound
guidance.
Subsequently,
efficacy
assessed,
biological
role
tryptophan
metabolite
kynurenine
(Kyn)
elucidated
through
both
vivo
vitro
experiments.
The
method
pre-hydration
at
4%
body
weight,
followed
post-cisplatin
(3.8
mg/kg)
2%
cisplatin-induced
survival
time
exceeding
28
days,
closely
mimicking
characteristics
typical
patients.
Additionally,
we
discovered
that
multiple
transplantations
promoted
function
recovery
more
effectively
than
single
via
catheter.
Furthermore,
elevated
levels
Kyn
were
observed
during
which
activated
aryl
hydrocarbon
receptor
(AhR)-mediated
NF-κB/NLRP3/IL-1β
signaling
pathway
tubular
epithelial
cells,
thereby
exacerbating
inflammatory
injury.
Ultrasound-guided
safe
effective
therapeutic
approach
bring
about
significant
advancements
future.
European journal of medical research,
Journal Year:
2025,
Volume and Issue:
30(1)
Published: March 22, 2025
Ischemic
stroke
(IS)
is
one
of
the
most
common
causes
disability
in
adults
worldwide.
This
study
aimed
to
identify
key
genes
related
inflammatory
response
provide
insights
into
mechanisms
and
management
IS.
Transcriptomic
data
for
IS
were
downloaded
from
Gene
Expression
Omnibus
(GEO)
database.
Weighted
gene
co-expression
network
analysis
(WGCNA)
differential
expression
used
inflammation-related
(IRGs)
associated
with
Hub
IRGs
screened
using
Lasso,
SVM-RFE,
random
forest
algorithms,
a
nomogram
diagnostic
model
was
constructed.
The
performance
assessed
receiver
operating
characteristic
(ROC)
curves
calibration
plots.
Additionally,
immune
cell
infiltration
potential
small
molecule
drugs
targeting
analyzed.
IRG
verified
by
qRT-PCR
healthy
controls
patients.
Nine
differentially
expressed
identified
IS,
including
NMUR1,
AHR,
CD68,
OSM,
CDKN1A,
RGS1,
BTG2,
ATP2C1,
TLR3.
Machine
learning
algorithms
selected
three
hub
(AHR,
NMUR1).
A
based
on
these
showed
excellent
an
area
under
curve
(AUC)
greater
than
0.9
both
training
validation
sets.
Immune
revealed
higher
levels
neutrophils
activated
CD4
+
T
cells,
lower
CD8
NK
naive
B
cells
exhibited
significant
correlations
infiltration.
Furthermore,
identified,
chrysin,
piperine,
genistein,
resveratrol,
which
have
therapeutic
effects
evaluation
demonstrated
that
blood
biomarkers
NMUR1)
patients
could
serve
as
distinguishing
indicators
between
(P
<
0.05).
confirmed
impact
progression
provided
new
targets
personalized
treatment
Probiotics and Antimicrobial Proteins,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 26, 2025
Spinal
cord
injury
(SCI)
disrupts
gut
flora
and
exacerbates
neuroinflammation.
Evidence
supports
the
important
role
of
intestinal
microbiota
in
SCI.
This
study
evaluated
neuroprotective
effect
Limosilactobacillus
reuteri
(L.
reuteri)
DSM
17938
on
SCI
its
potential
anti-inflammatory
mechanism.
The
was
disorganised
following
SCI,
with
a
significant
decrease
abundance
probiotic
bacteria
such
as
L.
reuteri.
DSM17938
treatment
improved
spinal
pathology
enhanced
locomotor
functional
recovery
SCI-model
rats.
Moreover,
it
modulated
tryptophan
metabolism
by
promoting
indole-3-carboxaldehyde
production.
In
addition,
inhibits
polarization
M1
microglia
reduces
production
IL-6,
IL-1
β,
TNF-α
to
alleviate
It
also
activates
aryl
hydrocarbon
receptor
(AhR)
signalling
via
upregulating
AhR
CYP1A1
expression,
tight
junction
protein
synthesis.
summary,
promotes
modulating
activate
barrier
repair
attenuate
microglial
activation
neuroinflammation,
suggesting
strategy
for
clinical
adjuvant
treatment.